Plain-English translation of NCT07793240 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
This research study is exploring whether a special blood test called Signatera can help doctors understand how well treatment is working for patients with high-grade upper tract urothelial cancer. The blood test looks for tiny pieces of cancer DNA that float in your bloodstream, which may help predict whether treatment is effective and whether surgery can be avoided or delayed.
Currently, doctors don't have good ways to monitor how well chemotherapy is working in this type of cancer before and after surgery. This study could help doctors make better decisions about whether to continue with surgery or try to save the kidney with chemotherapy alone.
You would have blood drawn at several time points: at the start of treatment, every 4 to 6 weeks while receiving chemotherapy, before and after any surgery, and during follow-up care. The blood samples would be sent to a laboratory to look for cancer DNA. This is an observational study, meaning researchers are watching and collecting information rather than testing a new medication โ your treatment itself would proceed as planned with your doctor.
AI-generated summary from trial data ยท Sep 16, 2026 ยท Not medical advice
United States
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Enrollment target
~20 participants
Started
December 2026
Primary completion
December 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in October 2026.
Reach out to the team running this trial. Response times vary โ some teams are faster than others.
Central contact
Sin Chan, MS
Johns Hopkins University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first โ no email needed to get started.